Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Immunocore Holdings plc

Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. 

See our community guidelines: http://bit.ly/2kFA8hr

Oxford Finance LLC

General Atlantic

Rock Springs Capital

RTW Investments

WuXi AppTec

Bill & Melinda Gates Foundation

Terra Magnum Capital Partners (""""TMCP"""")""

CCB International

JDRF T1D Fund

BlackRock

Immunocore

Unhealthy cells have evolved mechanisms for evading T cells, making diseases like cancer harder to treat. 

ImmTAC molecules contain a T cell receptor that has been engineered to better recognise its target and seek out evading cells. #IMCRSharing #innovation

It is by living our values daily that we are able to develop transformative treatments and to innovate for patients. #WeAreIMCR #innovation #ResearchAndDevelopment

Looking to advance your career in Regulatory Affairs? Apply for our Regulatory Submissions Manager position and grow within a highly innovative, agile, and entrepreneurial environment. https://lnkd.in/eu7WxW_v #WeAreIMCR #hiring #biotechjobs

Gynecologic cancers account for nearly 40% of cancer cases & 1/3 of cancer deaths in women. We must continue the search for new treatments & prevention measures to save the lives of women across the globe. #CervicalCancerPreventionWeek #CervicalCancerAwarenessMonth #WeAreIMCR

Come and apply the principles of effective clinical project practices at a pioneering biotech. #WeAreIMCR #biotechjobs #hiring
https://lnkd.in/eTSVJJcC

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	23.65M -	25.67M 8.52%	30.11M 17.32%	26.52M 11.93%	143.74M 441.99%	249.43M 73.53%
cost of revenue					454K -	1.04M 128.41%
gross profit	23.65M -	25.67M 8.52%	30.11M 17.32%	26.52M 11.93%	143.28M 440.28%	248.39M 73.36%
selling and marketing expenses	83.58M -	99.99M 19.64%
general and administrative expenses	34.16M -	44.18M 29.36%	45.74M 3.52%	88.40M 93.26%
selling general and administrative expenses	34.16M -	44.18M 29.36%	45.74M 3.52%	88.40M 93.26%	93.72M 6.02%	144.50M 54.17%
research and development expenses	83.58M -	99.99M 19.64%	74.81M 25.18%	73.23M 2.12%	89.17M 21.77%	163.54M 83.41%
other expenses	5.60M -	185K 96.70%	-1.15M 719.46%	57K 104.97%	-3K 105.26%	-897K 29,800%
cost and expenses	117.73M -	144.17M 22.46%	119.40M 17.18%	161.68M 35.41%	183.34M 13.40%	309.08M 68.58%
operating expenses	117.73M -	144.17M 22.46%	119.40M 17.18%	161.68M 35.41%	182.89M 13.12%	308.04M 68.43%
interest expense	842K -	3.80M 350.83%	3.11M 18.10%	5.81M 86.97%	7.69M 32.32%	5.15M 33.00%
ebitda	-80.95M -	-107.71M 33.07%	-75.45M 29.96%	-135.12M 79.09%	-36.45M 73.02%	-38.47M 5.53%
operating income	-93.45M -	-118.32M 26.61%	-86.19M 27.15%	-135.16M 56.81%	-39.61M 70.70%	-59.65M 50.60%
depreciation and amortization	6.71M -	10.61M 58.13%	10.75M 1.32%	47K 99.56%	3.15M 6,610.64%	4.09M 29.68%
total other income expenses net	5.92M -	-7.87M 232.94%	-1.17M 85.17%	-5.77M 394.09%	-4.54M 21.30%	-14.07M 210.11%
income before tax	-88.18M -	-126.19M 43.11%	-87.36M 30.77%	-140.93M 61.32%	-44.15M 68.68%	-60.89M 37.93%
income tax expense	-16.55M -	-22.26M 34.51%	-13.27M 40.39%	-9.40M 29.11%	-2.92M 68.94%	-5.60M 91.82%
net income	-71.63M -	-103.93M 45.09%	-74.09M 28.71%	-131.52M 77.51%	-41.22M 68.66%	-55.29M 34.11%
weighted average shs out	27.31B -	27.31B 0%	31.78M 99.88%	43.86M 38.01%	45.71M 4.22%	48.89B 106,843.14%
weighted average shs out dil	27.31B -	27.31B 0%	31.78M 99.88%	43.86M 38.01%	45.71M 4.22%	48.89B 106,843.14%
eps	-0.00 -	-0.00 46.15%	-2.33 61,215.79%	-3 28.76%	-0.90 70%	-0.00 99.88%
epsdiluted	-0.00 -	-0.00 46.15%	-2.33 61,215.79%	-3 28.76%	-0.90 70%	-0.00 99.88%

COM:IMMUNOCORE

Immunocore Holdings plc

Last Close

32.42

21/11 21:00

Market Cap

1.90B

Beta: -

Volume Today

168.16K

Avg: -

Preview